Signaling pathways and intervention for therapy of type 2 diabetes mellitus
Abstract Type 2 diabetes mellitus (T2DM) represents one of the fastest growing epidemic metabolic disorders worldwide and is a strong contributor for a broad range of comorbidities, including vascular, visual, neurological, kidney, and liver diseases. Moreover, recent data suggest a mutual interplay...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-06-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.283 |
| _version_ | 1797802500293656576 |
|---|---|
| author | Rong Cao Huimin Tian Yu Zhang Geng Liu Haixia Xu Guocheng Rao Yan Tian Xianghui Fu |
| author_facet | Rong Cao Huimin Tian Yu Zhang Geng Liu Haixia Xu Guocheng Rao Yan Tian Xianghui Fu |
| author_sort | Rong Cao |
| collection | DOAJ |
| description | Abstract Type 2 diabetes mellitus (T2DM) represents one of the fastest growing epidemic metabolic disorders worldwide and is a strong contributor for a broad range of comorbidities, including vascular, visual, neurological, kidney, and liver diseases. Moreover, recent data suggest a mutual interplay between T2DM and Corona Virus Disease 2019 (COVID‐19). T2DM is characterized by insulin resistance (IR) and pancreatic β cell dysfunction. Pioneering discoveries throughout the past few decades have established notable links between signaling pathways and T2DM pathogenesis and therapy. Importantly, a number of signaling pathways substantially control the advancement of core pathological changes in T2DM, including IR and β cell dysfunction, as well as additional pathogenic disturbances. Accordingly, an improved understanding of these signaling pathways sheds light on tractable targets and strategies for developing and repurposing critical therapies to treat T2DM and its complications. In this review, we provide a brief overview of the history of T2DM and signaling pathways, and offer a systematic update on the role and mechanism of key signaling pathways underlying the onset, development, and progression of T2DM. In this content, we also summarize current therapeutic drugs/agents associated with signaling pathways for the treatment of T2DM and its complications, and discuss some implications and directions to the future of this field. |
| first_indexed | 2024-03-13T05:06:37Z |
| format | Article |
| id | doaj.art-2c96ee446c84427ebf72c99991c72fb8 |
| institution | Directory Open Access Journal |
| issn | 2688-2663 |
| language | English |
| last_indexed | 2024-03-13T05:06:37Z |
| publishDate | 2023-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm |
| spelling | doaj.art-2c96ee446c84427ebf72c99991c72fb82023-06-16T09:40:37ZengWileyMedComm2688-26632023-06-0143n/an/a10.1002/mco2.283Signaling pathways and intervention for therapy of type 2 diabetes mellitusRong Cao0Huimin Tian1Yu Zhang2Geng Liu3Haixia Xu4Guocheng Rao5Yan Tian6Xianghui Fu7Department of Endocrinology and Metabolism State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University and Collaborative Innovation Center of Biotherapy Chengdu Sichuan ChinaDepartment of Endocrinology and Metabolism State Key Laboratory of Biotherapy and Cancer Center West China Medical School, West China Hospital Sichuan University Chengdu Sichuan ChinaDepartment of Endocrinology and Metabolism State Key Laboratory of Biotherapy and Cancer Center West China Medical School, West China Hospital Sichuan University Chengdu Sichuan ChinaDepartment of Endocrinology and Metabolism State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University and Collaborative Innovation Center of Biotherapy Chengdu Sichuan ChinaDepartment of Endocrinology and Metabolism State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University and Collaborative Innovation Center of Biotherapy Chengdu Sichuan ChinaDepartment of Endocrinology and Metabolism State Key Laboratory of Biotherapy and Cancer Center West China Medical School, West China Hospital Sichuan University Chengdu Sichuan ChinaDepartment of Endocrinology and Metabolism State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University and Collaborative Innovation Center of Biotherapy Chengdu Sichuan ChinaDepartment of Endocrinology and Metabolism State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University and Collaborative Innovation Center of Biotherapy Chengdu Sichuan ChinaAbstract Type 2 diabetes mellitus (T2DM) represents one of the fastest growing epidemic metabolic disorders worldwide and is a strong contributor for a broad range of comorbidities, including vascular, visual, neurological, kidney, and liver diseases. Moreover, recent data suggest a mutual interplay between T2DM and Corona Virus Disease 2019 (COVID‐19). T2DM is characterized by insulin resistance (IR) and pancreatic β cell dysfunction. Pioneering discoveries throughout the past few decades have established notable links between signaling pathways and T2DM pathogenesis and therapy. Importantly, a number of signaling pathways substantially control the advancement of core pathological changes in T2DM, including IR and β cell dysfunction, as well as additional pathogenic disturbances. Accordingly, an improved understanding of these signaling pathways sheds light on tractable targets and strategies for developing and repurposing critical therapies to treat T2DM and its complications. In this review, we provide a brief overview of the history of T2DM and signaling pathways, and offer a systematic update on the role and mechanism of key signaling pathways underlying the onset, development, and progression of T2DM. In this content, we also summarize current therapeutic drugs/agents associated with signaling pathways for the treatment of T2DM and its complications, and discuss some implications and directions to the future of this field.https://doi.org/10.1002/mco2.283β cell dysfunctionantidiabetic drugdiabetes complicationsinsulin resistancepathologytherapeutic target |
| spellingShingle | Rong Cao Huimin Tian Yu Zhang Geng Liu Haixia Xu Guocheng Rao Yan Tian Xianghui Fu Signaling pathways and intervention for therapy of type 2 diabetes mellitus MedComm β cell dysfunction antidiabetic drug diabetes complications insulin resistance pathology therapeutic target |
| title | Signaling pathways and intervention for therapy of type 2 diabetes mellitus |
| title_full | Signaling pathways and intervention for therapy of type 2 diabetes mellitus |
| title_fullStr | Signaling pathways and intervention for therapy of type 2 diabetes mellitus |
| title_full_unstemmed | Signaling pathways and intervention for therapy of type 2 diabetes mellitus |
| title_short | Signaling pathways and intervention for therapy of type 2 diabetes mellitus |
| title_sort | signaling pathways and intervention for therapy of type 2 diabetes mellitus |
| topic | β cell dysfunction antidiabetic drug diabetes complications insulin resistance pathology therapeutic target |
| url | https://doi.org/10.1002/mco2.283 |
| work_keys_str_mv | AT rongcao signalingpathwaysandinterventionfortherapyoftype2diabetesmellitus AT huimintian signalingpathwaysandinterventionfortherapyoftype2diabetesmellitus AT yuzhang signalingpathwaysandinterventionfortherapyoftype2diabetesmellitus AT gengliu signalingpathwaysandinterventionfortherapyoftype2diabetesmellitus AT haixiaxu signalingpathwaysandinterventionfortherapyoftype2diabetesmellitus AT guochengrao signalingpathwaysandinterventionfortherapyoftype2diabetesmellitus AT yantian signalingpathwaysandinterventionfortherapyoftype2diabetesmellitus AT xianghuifu signalingpathwaysandinterventionfortherapyoftype2diabetesmellitus |